DSG Press Releases - 2009
DSG SPARKS DIALOGUE, DEMONSTRATES VISION AT 2009 SCDM ANNUAL CONFERENCE — DSG’s EDC presence at 2009 SCDM conference delivered on high expectations —
MALVERN, Pa., October 26, 2009 — DSG, Inc., the leader in EDC and clinical software technology, sparked a robust dialogue and inspired attendees at the 2009 SCDM Annual Conference in Seattle recently, again proving its role as a pioneer in the EDC (electronic data capture) field. Over 500 eager attendees experienced the latest EDC developments, learned how to successfully navigate a critical industry challenge and saw the future of EDC from DSG.
DSG IN THE SPOTLIGHT AT 2009 SCDM ANNUAL CONFERENCE
MALVERN, Pa., October 1, 2009 — DSG, Inc., the leader in EDC and clinical software technology, is already the center of attention leading up to the 2009 SCDM Annual Conference. The excitement is centered around DSG’s continuing role as a pioneer in the EDC (electronic data capture) field, with over 500 attendees eager to see the latest developments and the future of EDC from DSG.
CIPHER USES DSG’S EDC IN EFFORT TO GIVE HOPE TO SEVERE ACNE SUFFERERS
MALVERN, Pa., September 14, 2009 — DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX: DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne.
DSG TOPS CLINICAL TRIAL MARKET ON THE INC. 500
MALVERN, Pa., August 31, 2009 — The Inc. 500, which ranks the fastest growing U.S. privately held companies, announced that DSG reached No. 82 in the nation, making it the fastest growing privately held company in the Philadelphia area. As an Inc. 500 honoree, DSG shares a prestigious pedigree with such notable companies as Intuit, Microsoft, and Oracle.
HUMAN GENOME ACHIEVES LUPUS DRUG GOALS WITH DSG’S EDC
MALVERN, Pa., Aug. 17, 2009 —Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA™ has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.
DSG ANNOUNCES RECORD GROWTH FOR THE FIRST HALF OF 2009
SAN DIEGO, June 22, 2009 — DSG Inc., an industry leader in clinical trial data collection and management, today announced, from the 45th Annual Meeting of the Drug Information Association, its continued record growth and profitability for the first half of 2009.
DSG CEO TONY VARANO NAMED ERNST & YOUNG ENTREPRENEUR OF THE YEAR 2009 IN GREATER PHILADELPHIA
MALVERN, Pa., May 26, 2009 — DSG, Inc. today announced that CEO Tony Varano is a finalist for the Ernst & Young Entrepreneur Of The Year® 2009 Award in the Greater Philadelphia.
DSG TO EXHIBIT LATEST IN ELECTRONIC DATA CAPTURE AT 18th ANNUAL PARTNERSHIPS WITH CROs CONFERENCE
MALVERN, Pa., April 20, 2009 — DSG Inc., an industry leader in clinical trial data collection and management, will be exhibiting at the 18th Annual Partnerships with CROs Conference at the Orlando Rosen Shingle Creek Hotel and Conference Center, April 28-30, 2009.
DSG TO HOST ANNUAL USER'S GROUP MEETING
MALVERN, Pa., Feb 26, 2009 - DSG. Inc., an industry leader in clinical trial data collection and management, today announced that it will host its annual User’s Group Meeting on March 26, 2009 at the Trump Plaza Hotel and Casino in Atlantic City, N.J.
DSG WINS SCDM'S DATA DRIVEN INNOVATION AWARD FOR CLINICAL DATA QUALITY CONTROL IMPLEMENATION AT HUMAN GENOME SCIENCES
MALVERN, Pa., Jan. 12, 2009 — DSG. Inc., an industry leader in clinical trial data collection and management, today announced that its collaborative work with Human Genome Sciences (HGS) was selected as the second place winner in the 2008 Society For Clinical Data Management (SCDM) Data Driven Innovation Award competition.